SELLAS Life Sciences Group announced that its Phase 3 REGAL trial of experimental cancer vaccine galinpepimut-S (GPS) met its primary endpoint, demonstrating a 41% reduction in the risk of death among patients with acute myeloid leukemia (AML).
The study involved 126 patients who achieved a second remission but were ineligible for an allogeneic stem cell transplant.
SELLAS CEO Angelos Stergiou described the results as a validation of the company’s WT1-targeted immunotherapy technology.
The company plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy and is preparing for a Biologics License Application submission in the first half of 2027.
Related Tweet:
A first of its kind vaccine for acute myeloid leukemia, a deadly blood cancer, succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced. https://t.co/RjBzKDNHif
— The Washington Post (@washingtonpost) November 18, 2026
Also Read:

